References
- Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41:471–483.
- Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther. 2000;67:7–15.
- Hatorp V, Oliver S, Su C. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther. 1998;36:636–641.
- Bidstrup TB, Bjørnsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Brit J Pharmacol. 2003;56:305–314.
- Niemi M, Leathart JB, Neuvonen M, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003;74:380–387.
- Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide’s pharmacokinetics. Pharmacology. 2010;85:357–364.
- Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Brit J Pharmacol. 2008;66:818–825.
- Perentesis GP, Damsbo P, Muller PG. Single dose pharmacokinetics and pharmacodynamics of repaglinide in type 2 diabetic patients. J Clin Pharmacol. 1994;34:1021.
- Schmitz O, Jonler M, Lund S, et al. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care. 2002;25:342–346.
- Product Information: PRANDIN(R) oral tablets, repaglinide oral tablets. Princeton (NJ): Novo Nordisk Inc. (per FDA); 2012.
- Nakayama S, Hirose T, Watada H, et al. Hypoglycemia following a nateglinide overdose in a suicide attempt. Diabetes Care. 2005;28:227–228.
- Hirshberg B, Skarulis MC, Pucino F, et al. Repaglinide-induced factitious hypoglycemia. J Clin Endocr Metab. 2001;86:475–477.
- Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health-Syst Ph. 2006;63:929–938.
- Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165:216–224.
- Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC − MS/MS. Anal Chem. 2003;75:3019–3030.
- De Leon DD, Stanley CA. Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2013;27:763–769.
- Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94:709–728.
- Guenat E, Seematter G, Philippe J, et al. Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations. Diabetes Metab. 2000;26:377–384.